News Releases Keyword Search Year None202420232022202120202019201820172016 Jul-15-2024 Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer Jul-11-2024 Oncternal Therapeutics to Present in JonesTrading Healthcare Summit May-30-2024 Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer May-09-2024 Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results May-02-2024 Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results May-01-2024 Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Apr-18-2024 Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer Mar-15-2024 Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer Mar-07-2024 Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results Feb-29-2024 Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »